Cardiac fibrosis remains an attractive therapeutic target, but unfortunately, inhibition of TGFβ failed in the clinic due to on-target toxicities, which include inflammation and cardiac impairment [31,32]. This evidence concerns the gene TGFB1 and fibrosis.